Published in final edited form as:

Cancer Epidemiol Biomarkers Prev. 2010 August ; 19(8): 1966–1975. doi:
10.1158/1055-9965.EPI-10-0270.

Serum pepsinogens and *Helicobacter pylori* in relation to the risk of esophageal squamous cell carcinoma in the ATBC Study

Michael B. Cook¹, Sanford M. Dawsey¹, Lena Diaw², Martin J. Blaser³, Guillermo I. Perez-Perez³, Christian C. Abnet¹, Philip R. Taylor¹, Demetrius Albanes¹, Jarmo Virtamo⁴, and Farin Kamangar^{1,5}

¹ Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD ² Pulmonary and Vascular Medicine Branch, National Heart, Lung, and Blood Institute, NIH, DHHS, Bethesda, MD ³ Departments of Medicine and Microbiology, School of Medicine, New York University, New York, NY ⁴ Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland ⁵ Department of Public Health Analysis, School of Community Health and Policy, Morgan State University, Baltimore, MD

Abstract

Background—*Helicobacter pylori* (*H. pylori*) can induce gastric atrophy in humans, which in turn increases gastric cancer risk. Whether *H. pylori* and gastric atrophy also affect the risk of esophageal squamous cell carcinoma (ESCC), however, remains unresolved.

Methods—We performed a nested case-control study within the prospective ATBC Study to assess these relationships. The ATBC Study is composed of 29,133 Finnish male smokers, aged 50–69, who were recruited during 1985–1988. Using baseline sera, we assessed *H. pylori* status (via IgG antibodies against whole-cell and CagA antigens) and gastric atrophy status (via the biomarkers pepsinogen I (PGI) and II (PGII)) in 79 ESCC cases and 94 controls. Logistic regression with adjustment for age, date of blood draw, education, cigarette smoking, alcohol, body mass index, and fruit and vegetable intake was used to estimate odds ratios (OR) and 95% confidence intervals (95%CI).

Results—Gastric atrophy (PGI:PGII <4) was associated with ESCC (OR=4.58, 95%CI:2.00–10.48). There was no evidence for an association between *H. pylori* and ESCC (OR=0.94, 95%CI: 0.40–2.24).

Conclusions—These results could be explained by misclassification of *H. pylori* status due to serologic amnesia, ESCC risk being dependent upon the functional consequences or interactions of *H. pylori*, rather than the infection *per se*, gastric atrophy having a different histogenesis in ESCC without being primarily dependent upon *H. pylori* acquisition, or a lack of statistical power to detect an effect.

Impact—Validation of these results may warrant mechanistic studies to determine the route of association between gastric atrophy and ESCC.

Corresponding author: Michael Blaise Cook, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, 6120 Executive Blvd, EPS/Suite 550/Room 5030, Bethesda, MD 20852-7234, phone: 301-496-1613, fax: 301-402-0916, michael.cook@nih.gov.

There are no financial disclosures from any of the authors.

Keywords (MeSH)

Atrophy; Esophageal Neoplasms; *Helicobacter pylori*; Nested Case-Control Studies; Pepsinogens; Prospective Studies

Introduction

During the last 40 years, incidence trends and global patterns of esophageal adenocarcinoma and esophageal squamous cell carcinoma (ESCC) have indicated that there are strong environmental risk factors that we are yet to elucidate. Esophageal adenocarcinoma has been rapidly increasing in many predominantly Caucasian, developed countries of the western world while ESCC has been declining (1,2). Many countries in east and central Asia have not observed such trends and squamous cell carcinoma remains the principal esophageal malignancy reported (3–5).

Helicobacter pylori is a gram-negative bacterium which has been colonizing the gastric epithelium of humans since at least prior to their migration from east Africa 58,000 years ago (6). This bacterium colonizes approximately half of the world population, but its prevalence in developed countries has been declining (7). In 1994, the International Agency for Research on Cancer (IARC) categorized *H. pylori* as a group I carcinogen (8), due to overwhelming evidence of its association with noncardia gastric adenocarcinoma (7). Its association with ESCC, however, is uncertain; a recent systematic review and meta-analysis endorsed the null hypothesis, albeit with a high degree of heterogeneity, and with study-specific statistically significant associations in both directions (9). A subgroup analysis of western studies showed a statistically significant association with ESCC, although this used a broader definition of *H. pylori* positivity and included only four studies.

Persistent *H. pylori* colonization promotes the induction of gastric atrophy which is considered to be part of the causal pathway of intestinal-type gastric adenocarcinoma (10,11). Pepsinogens are aspartic proteinases that are predominantly produced and secreted into the gastric lumen by gastric epithelial cells. They can be categorized into two groups: Pepsinogen I (PGI) which is produced only by the gastric fundic mucosa, and pepsinogen II (PGII) which is produced by the fundic, cardiac and antral mucosa of the stomach, and also by the duodenal mucosa (12). The progression of gastric atrophy leads to reduced fundic chief cell mass which decreases PGI (13). PGII, however, stays relatively stable or may undergo a slight increase (13). Therefore, the PGI:PGII ratio is a sensitive and specific biomarker of gastric atrophy (14,15).

Prior studies that have assessed gastric atrophy in relation to ESCC risk came to conflicting conclusions (16–21). Evidence for a causal relationship has been limited, since four of these six studies used a case-control design (16,17,20,21). Therefore, we designed a nested case-control study within the prospective Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study to assess whether *H. pylori* and gastric atrophy were associated with risk of ESCC in this cohort.

Methodology

ATBC Study

The rationale, design and results of the ATBC Study have been described in detail (22). In brief, the ATBC Study was a randomized, double-blind, placebo-controlled, 2 x 2 factorial primary prevention trial that tested whether daily supplementation with alpha-tocopherol (50 mg) and/or beta-carotene (20 mg) could reduce the incidence of lung and other cancers. A

total of 29,133 male smokers, aged 50–69 and living in southwestern Finland, were recruited from 1985 to 1988. The intervention concluded on April 30, 1993, but the participants continue to be followed as a cohort. The ATBC Study was approved by the institutional review boards of the National Cancer Institute, Bethesda, Maryland, and the National Public Health Institute, Helsinki, Finland. All subjects provided written informed consent. At the pre-randomization baseline visit, study participants completed questionnaires on demographic characteristics and provided information regarding their medical, dietary, and smoking history. Their weights and heights were measured by trained study staff. Blood samples were collected from participants at two time points: at baseline (1985–1988) and 3 years after randomization. The sera were stored at -70°C . All sera used for this analysis were collected at baseline.

Study subjects and serum pepsinogen and *Helicobacter pylori* measurement

Cases were individuals who were diagnosed with ESCC in the ATBC study through April 30th, 2005. ESCC was defined according to the International Classification of Diseases, 9th Revision (23) code 150 and the International Classification of Diseases for Oncology, 2nd Edition (24) codes 8050–8078. Eligible cases were required to have at least 200 μL of serum available for analysis. Controls were matched to cases on age at randomization (± 5 years) and date of blood draw (± 30 days) and were required to be alive and cancer-free up until the date of cancer diagnosis of their matched case.

Serum PGI and PGII were assayed blinded to case-control status in duplicate in the same batch using an enzyme-linked immunosorbent assay (Biohit ELISA kit, Finland). The average of the duplicate values for PGI and for PGII were used for analysis. Duplicate results were strongly correlated: Pearson's correlation coefficient was 0.998 for PGI and 0.997 for PGII. In addition, 15 quality control samples, aliquoted from a single large pool of serum from ATBC study participants, were distributed among the 5 assay plates (3 samples per plate). On the basis of these samples, the coefficients of variation were 6.0% and 8.7% for PGI and PGII, respectively.

Helicobacter pylori seropositivity was assessed using immunoglobulin G antibodies against *H. pylori* whole-cell and CagA antigens by enzyme linked immunosorbent assays, as described (25). Seropositivity was defined as an optical density ratio of ≥ 1.0 for the whole-cell antigen assay and ≥ 0.35 for the CagA antigen assay. Serum samples were assayed in duplicate in the same batch blinded to case-control status. Fifteen quality control serum samples, aliquoted from a single large pool, were equally distributed among the 5 batches. On the basis of these samples, the coefficients of variation for *H. pylori* whole-cell and CagA antigen assays were 7.8% and 11.8%, respectively.

Statistical analysis

Serum pepsinogen I (PGI), serum pepsinogen II (PGII) and the ratio of these biomarkers (PGI:PGII) were analyzed as continuous, dichotomous and ordinal (quartiles) variables. For the continuous analyses, a single unit increase was equal to half the distance between the 25th and 75th percentile values (the average size of the two central quartiles) of control subjects (19,26). The units of such were 38.99 $\mu\text{g/L}$ for PGI, 5.93 $\mu\text{g/L}$ for PGII, and 2.00 for the PGI:PGII ratio. For the dichotomous analyses, the cut-points were the 50th percentile of the control distribution for PGI and PGII and the value of 4 for PGI:PGII, the latter of which we have used in previous pepsinogen analyses (19,26). We also conducted additional dichotomous analyses of PGI using the cut-points of the 75th percentile of the control distribution, 70 $\mu\text{g/L}$, 50 $\mu\text{g/L}$ and 30 $\mu\text{g/L}$; analyses of PGI:PGII using the cut-points of the 75th percentile of the control distribution, the 50th percentile of the control distribution, and the ratios 5, 3 and 2; and analyses of two combinations of PGI:PGII ratios and PGI values,

including a PGI:PGII ratio of 3 and a PGI of 70 µg/L, and a PGI:PGII ratio of 2 and a PGI of 30 µg/L. These analyses were designed to assess the full range of the pepsinogen distributions, to provide results for comparison to previous publications, and for use in future meta-analyses. For the ordinal analyses, pepsinogen categories were based on quartiles of the control distributions.

H. pylori status was assessed as a dichotomous variable, whereby an individual was classed as exposed if the assay for antibodies to whole cell *or* CagA was positive (27). We also analyzed *H. pylori* as a categorical variable, comparing whole cell positive/CagA-negative individuals, and CagA-positive individuals to the referent group of whole cell-negative/CagA-negative.

Serum pepsinogens and *H. pylori* were assessed in relation to risk of ESCC using conditional logistic regression to estimate odds ratios (OR) and 95 percent confidence intervals (95%CI). We also conducted unconditional logistic analyses adjusted for the matching factors of age at randomization and date of blood draw. Fully adjusted estimates were also ascertained from models which included the additional covariates of education (dichotomous), duration and intensity of cigarette smoking, alcohol, body mass index, fruit consumption, and vegetable consumption. Unless otherwise specified, these exposures were modeled as continuous variables. Estimates derived from conditional and unconditional logistic regression models were similar, thus only the results from the unconditional models are presented herein as this methodology allowed inclusion of a greater number of individuals. We also examined the shape of the association between pepsinogens and ESCC using nonlinear models adjusted for all covariates via PROC GAM in SAS. After fitting the generalized additive model, we plotted the odds ratios of ESCC on the logarithmic scale versus PGI, PGII and PGI:PGII ratio on the linear scale. Lastly, we conducted some exploratory analyses of the effect of the primary exposures on ESCC risk stratified by: cancer site [upper (ICD9 150.3), middle (150.4), and lower (150.5) esophagus]; tertiles of time between date of blood draw and cancer diagnosis; alcohol consumption dichotomized by the median alcohol consumption per day of controls; and cigarette smoking dichotomized by median pack-years of controls. The first two of these exploratory analyses were adjusted only for the matching variables, due to small numbers, and the latter two analyses were fully adjusted. In addition, product-term models, with continuous metrics centered (28), were conducted to assess potential multiplicativity (29) between *H. pylori* and alcohol consumption, and *H. pylori* and cigarette smoking, in relation to ESCC. Two-sided p-values <0.05 were considered to be statistically significant. All analyses were conducted using STATA version 10.1 (Stata-Corp LP, College Station, TX), and SAS version 9.2 (SAS Institute, Cary, NC).

Results

Descriptive characteristics of ESCC cases and controls are shown in Table 1. There were no differences in age, years of smoking, cigarettes per day, or body mass index. On average, ESCC cases consumed more alcohol, received less formal education, and consumed less fruit and vegetables, compared with controls. The median time between date of randomization and date of diagnosis for the ESCC cases was 9.94 years.

Table 2 shows the results of the logistic regression analyses. PGI was found to be inversely associated with ESCC risk (OR=1.49 per-unit decrease, 95%CI:1.13–1.96). When dichotomized using the 50th percentile of the control distribution (152 µg/L), the risk of ESCC was increased two-fold in the lower PGI category compared with the higher PGI category. Moreover, risk estimates increased in magnitude in a monotonic manner as the PGI cut-point decreased, culminating in an OR of 5.12 (95%CI:1.79–14.67) for individuals

with a PGI value of ≤ 30 $\mu\text{g/L}$. The ordinal analysis of PGI also supported an association with ESCC risk ($\text{OR}_{Q2}=1.77$, 95% CI:0.65–4.79; $\text{OR}_{Q3}=2.50$, 95% CI:0.94–6.64; $\text{OR}_{Q4}=3.40$, 95% CI:1.30–8.86). The results for PGII were mostly null. These observations are strengthened by plots of the relationship between PGI and PGII with ESCC risk (Figures 1 & 2).

The PGI:PGII ratio was, like PGI, found to be inversely associated with ESCC risk. When analyzed as a continuous metric, the OR per-unit decrease was 1.48 (95% CI:1.17–1.87). A PGI:PGII ratio ≤ 4 was associated with a four-and-a-half-fold increased risk of ESCC ($\text{OR}=4.58$, 95% CI:2.00–10.48) and this risk increased with more stringent (lower) cut-points. The highest risk was observed when using the combined cut-point of PGI:PGII ratio ≤ 2 & PGI ≤ 30 ; these individuals had an increased ESCC risk of 6.28 (95% CI:1.90–20.77). When analyzed by quartiles, only the lowest quartile (PGI:PGII ratio <4.86) was associated with an increased risk of ESCC. However, the various dichotomous analyses and the generalized additive model of the relationship (Figure 3) indicate that the relationship between PGI:PGII and ESCC is monotonic.

Analysis of a combined, categorical variable of PGI and PGII, defined using the 50th percentiles of the control distributions found only the category of low PGI and low PGII was associated with risk of ESCC ($\text{OR}=2.42$, 95% CI:1.00–5.86), as may be expected given the previously discussed results.

H. pylori was not associated with ESCC ($\text{OR}=0.94$, 95% CI:0.40–2.24). Similarly null estimates were obtained for whole cell positive/CagA negative, and CagA positive groups, compared with individuals negative for *H. pylori* (Table 2).

Lastly, exploratory analyses of pepsinogens stratified by ESCC site (upper, middle, and lower thirds) provided similar estimates of association across sites (Supplementary Table 1). Exploratory analyses of ESCC risk stratified by time between blood draw and cancer diagnosis suggested a stronger association between *H. pylori* seropositivity and ESCC in the longest time category (>13.24 years; $\text{OR}=3.45$, 95% CI:0.74–16.01) relative to estimates of the middle (>7.89 & ≤ 13.24 years; $\text{OR}=1.07$, 95% CI:0.37–3.07) or shortest (≤ 7.89 years; $\text{OR}=0.90$, 95% CI:0.31–2.59) time categories (Supplementary Table 2). However, this highest risk did not reach statistical significance, the numbers for analysis were fairly modest, and the derived estimates were only minimally adjusted. Exploratory analyses stratified by median alcohol consumption (Supplementary Table 3), median pack-years of cigarette smoking (Supplementary Table 4), and product-term models of such ($p=0.128$ and $p=0.844$, respectively) indicated no evidence for multiplicativity of risk.

Discussion

This case-control study, nested within the prospective ATBC Study, provides evidence that serological biomarkers of gastric atrophy are associated with risk of ESCC. PGI levels and the PGI:PGII ratio were both statistically significantly related to ESCC when analyzed as continuous, dichotomous, and ordinal metrics. The full range of analyses and nonlinear modeling of relationships indicated that PGI and PGI:PGII ratio have fairly monotonic relationships with ESCC risk. Thus, gastric atrophy may play a role in the pathogenesis of ESCC, although no association was found with *H. pylori*, the primary inducer of gastric atrophy.

The first indication of a potential relationship between gastric atrophy and ESCC was provided in 1979 when a case-series of 97 esophageal cancer patients found 63 cases to harbor moderate to marked atrophic gastritis (30). In 1993, a second study confirmed this observation (31), and a Swedish cohort study noted a three-fold increased risk of esophageal

cancer (88% of which was ESCC) in individuals with pernicious anemia, an ailment associated with severe gastric atrophy (32).

Subsequent to these initial observations, six studies (16–21) have formally tested the hypothesis that gastric atrophy is associated with ESCC (Table 3). As can be seen, all studies which assessed this relationship, whether using serology, histology, or endoscopic appearance for ascertainment of gastric atrophy, found evidence for an association with ESCC which, in totality, provides convincing evidence that the association is real. It remains less clear, however, whether this relationship is causal or results from confounding. If increased severity of gastric atrophy were associated with increased risk of ESCC, this would strengthen the case for the association being causal. Indeed, this is what we found in the current study from the statistical models and graphical representations of the association between PGI, PGI:PGII ratio, and ESCC. Yokoyama et al (20) also found evidence for a monotonic pattern of association between serum pepsinogens and ESCC in a Japanese population. Further evidence for this pattern has also been provided by a previous study which we conducted in China (26) in which we demonstrated a monotonic association between PGI:PGII ratio and esophageal squamous dysplasia, which is a known precursor lesion of ESCC (33,34). Conversely, there is evidence from serum pepsinogen analyses which do not support a monotonic pattern with ESCC risk (17,19) (Table 3); although it should be noted that the results from Iijima *et al*'s (17) ordinal analysis of PGI:PGII (*pers. comm.* Dr. K. Iijima, Division of Gastroenterology, Tohoku University Graduate School of Medicine, Japan) are not too dissimilar to the equivalent analysis contained herein, and more extensive scrutiny of the data could prove informative.

Table 3 also shows that some studies have used other proxy measures to estimate atrophic severity: endoscopy for ascertainment of maximal atrophic extent, and histopathology to ascertain whether an individual harbors intestinal metaplasia or dysplasia. Both of these measures are likely to be inferior relative to serum pepsinogens as proxies of atrophic severity. Endoscopic assessment of atrophic extent is a subjective measurement, and it can be difficult to delineate between atrophic and normal tissues using standard endoscopic visualization (35). Histologic diagnosis is subject to sampling bias and inconsistent interpretation (36,37), both of which may cause misclassification and bias results towards the null. Conversely, serum pepsinogens are an objective measure which provides a global representation of the extent of gastric atrophy.

The Dutch study (18) reasoned that because ESCC risk did not increase with gastric carcinogenic progression (gastric atrophy to intestinal metaplasia to dysplasia) this was evidence for non-causality. Although degree of intestinal metaplasia, using the Sydney Classification scheme, and the number of gastric biopsies positive for intestinal metaplasia have been correlated with severity of atrophic gastritis (38,39), it has not, to our knowledge, been shown that gastric carcinogenic progression (gastric atrophy to intestinal metaplasia to dysplasia) is similarly correlated. In addition, atrophic gastritis is likely to be sufficient for an increased risk of ESCC regardless of intestinal metaplasia and dysplasia status, especially given that the sites of exposure and outcome are distinct.

The Dutch study (18) does, however, present the most persuasive evidence that the relationship between gastric atrophy and ESCC could be the result of confounding. In addition to their analyses of ESCC, they reported an association between gastric atrophy and small cell lung carcinoma, a relationship which may be difficult to reconcile biologically. In our analyses, adjustment for the major risk factors of ESCC did not change the results, although we cannot rule out the possibility of residual confounding, a problem inherent to all observational epidemiologic studies. Further studies are needed to clarify the issue of causality in the relationship between gastric atrophy and ESCC risk.

We found no association between *H. pylori* and ESCC, in agreement with the results of a recent meta-analysis (9). This lack of association is not necessarily contradictory to our pepsinogen results; there are at least three possible explanations. First, by the age of entry into this study, *H. pylori* colonization may have burned itself out, by inducing gastric atrophy and thus destroying the environment in which it thrives, which could result in serologic amnesia (40). However, we found no difference in the estimates for the association of *H. pylori* and ESCC risk when we stratified the analysis by time between blood draw and cancer diagnosis (Supplementary Table 2); even in those with serum drawn with the shortest time period between blood draw and cancer diagnosis, 20 out of 26 individuals were still *H. pylori* seropositive. A second alternative is that ESCC risk could be dependent upon the functional consequences or interactions of *H. pylori*, rather than its presence *per se*; for example, whether it is able to induce hypochlorhydria (41) or whether an additional exposure, such as alcohol (42), increases the likelihood of atrophy, although an analysis stratified by alcohol consumption (Supplementary Table 3) and a product-term model of our data ($p=0.128$) indicated no evidence for multiplicativity. A third alternative is that gastric atrophy/hypochlorhydria could have a different histogenesis in ESCC and may not be primarily dependent upon *H. pylori* acquisition. A subset of patients with atrophic gastritis are *H. pylori*-negative (43,44), and *Acinetobacter lwoffii* is known to cause gastric atrophy in mice (45). However, in the present study, only a single case and no controls were *H. pylori*-negative and had a PGI:PGII ratio of less than 4.

Regardless of *H. pylori*'s contribution to ESCC carcinogenesis, the evidence indicates that gastric atrophy and hypochlorhydria (41) are associated with an increased risk of ESCC, but the mechanistic link remains to be elucidated. Bacterial overgrowth and duodenal reflux are possible consequences of atrophy that may play a role. Quantitative and qualitative changes in the microbiota of the gut resulting from hypochlorhydria (46,47) could cause increased N-nitrosation reactions, exerting carcinogenic effects on the esophageal mucosa (10,11). Duodenal reflux is also known to be carcinogenic (48), but requires both gastroesophageal and pyloric sphincters to be defective. Distally located ESCC has been associated with severe hypochlorhydria (41) and gastrectomy (49,50), the latter of which vastly increases the propensity for duodenal reflux (51). Countering this are our exploratory analyses which provided similar estimates of association between gastric atrophy and ESCC across esophageal sites (upper, middle, and lower thirds; Supplementary Table 1). However, there is also evidence, from animal models (52–55) and human epidemiologic studies (56–59) that other squamous cell carcinomas of the upper gastrointestinal tract may also be associated with duodenal reflux.

Strengths of our study include the prospective design with long-term follow-up; use of pre-diagnostic serum for analysis of PGI, PGII, and *H. pylori* antibodies; use of continuous, dichotomous, and ordinal models to interrogate associations; and the availability of covariate information for adjustment of potential confounders. Limitations include modest sample size, a population which includes only male smokers, the possibility of residual confounding, and imperfect correlation between pepsinogen metrics and the true severity of gastric atrophy. Residual confounding could be manifested in the microbiome, which is known to adjust to changes in gastric pH and may also be associated with ESCC risk.

In summary, we have shown that biomarkers of gastric atrophy (PGI and PGI:PGII ratio) are associated with risk of ESCC in the ATBC Cancer Prevention Study. We also find no evidence to suggest that *H. pylori*, *per se*, is causal in this relationship. Studies investigating the mechanism relating gastric atrophy and resultant hypochlorhydria to ESCC risk are warranted.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This research was supported in part by the Intramural Research Program of the NIH, NCI, Division of Cancer Epidemiology and Genetics

We thank Dr. K. Iijima (Division of Gastroenterology, Tohoku University Graduate School of Medicine, Japan) for his personal communication detailing additional analyses of his study.

References

1. Cook MB, Chow WH, Devesa SS. Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977–2005. *Br J Cancer* 2009;101:855–9. [PubMed: 19672254]
2. Bosetti C, Levi F, Ferlay J, et al. Trends in oesophageal cancer incidence and mortality in Europe. *Int J Cancer* 2008;122:1118–29. [PubMed: 17990321]
3. He YT, Hou J, Chen ZF, et al. Trends in incidence of esophageal and gastric cardia cancer in high-risk areas in China. *Eur J Cancer Prev* 2008;17:71–6. [PubMed: 18287862]
4. Lu CL, Lang HC, Luo JC, et al. Increasing trend of the incidence of esophageal squamous cell carcinoma, but not adenocarcinoma, in Taiwan. *Cancer Causes Control* 2010;21:269–74. [PubMed: 19866363]
5. Islami F, Kamangar F, Aghcheli K, et al. Epidemiologic features of upper gastrointestinal tract cancers in Northeastern Iran. *Br J Cancer* 2004;90:1402–6. [PubMed: 15054463]
6. Linz B, Balloux F, Moodley Y, et al. An African origin for the intimate association between humans and *Helicobacter pylori*. *Nature* 2007;445:915–8. [PubMed: 17287725]
7. Suerbaum S, Michetti P. *Helicobacter pylori* infection. *N Engl J Med* 2002;347:1175–86. [PubMed: 12374879]
8. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans., International Agency for Research on Cancer. Schistosomes, liver flukes and *Helicobacter pylori*. Geneva: The Agency : Secretariat of the World Health Organization [distributor]; 1994.
9. Islami F, Kamangar F. *Helicobacter pylori* and Esophageal Cancer Risk: A Meta-analysis. *Cancer Prev Res* 2008;1:329–38.
10. Correa P. A human model of gastric carcinogenesis. *Cancer Res* 1988;48:3554–60. [PubMed: 3288329]
11. Fox JG, Wang TC. Inflammation, atrophy, and gastric cancer. *J Clin Invest* 2007;117:60–9. [PubMed: 17200707]
12. Samloff IM, Taggart RT. Pepsinogens, pepsins, and peptic ulcer. *Clin Invest Med* 1987;10:215–21. [PubMed: 3113799]
13. Samloff IM, Varis K, Ihama K, Siurala M, Rotter JJ. Relationships among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology. A study in relatives of patients with pernicious anemia. *Gastroenterology* 1982;83:204–9. [PubMed: 7084603]
14. Iijima K, Abe Y, Kikuchi R, et al. Serum biomarker tests are useful in delineating between patients with gastric atrophy and normal, healthy stomach. *World J Gastroenterol* 2009;15:853–9. [PubMed: 19230047]
15. Kamangar F, Dawsey SM, Abnet CC, et al. Serum pepsinogens and risk of gastric cardia and noncardia cancers: A prospective study of 22,000 subjects. *Cancer Epidemiology Biomarkers & Prevention* 2005;14:2738S–9S.
16. Ye W, Held M, Lagergren J, et al. *Helicobacter pylori* infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. *J Natl Cancer Inst* 2004;96:388–96. [PubMed: 14996860]
17. Iijima K, Koike T, Abe Y, et al. Extensive gastric atrophy: an increased risk factor for superficial esophageal squamous cell carcinoma in Japan. *Am J Gastroenterol* 2007;102:1603–9. [PubMed: 17488251]

18. de Vries AC, Capelle LG, Looman CW, et al. Increased risk of esophageal squamous cell carcinoma in patients with gastric atrophy: independent of the severity of atrophic changes. *Int J Cancer* 2009;124:2135–8. [PubMed: 19107937]
19. Ren JS, Kamangar F, Qiao YL, et al. Serum pepsinogens and risk of gastric and oesophageal cancers in the General Population Nutrition Intervention Trial cohort. *Gut* 2009;58:636–42. [PubMed: 19136509]
20. Yokoyama A, Omori T, Yokoyama T, et al. Chronic atrophic gastritis and metachronous gastric cancer in Japanese alcoholic men with esophageal squamous cell carcinoma. *Alcohol Clin Exp Res* 2009;33:898–905. [PubMed: 19320631]
21. Akiyama T, Inamori M, Iida H, et al. Macroscopic extent of gastric mucosal atrophy: increased risk factor for esophageal squamous cell carcinoma in Japan. *BMC Gastroenterol* 2009;9:34. [PubMed: 19450276]
22. ATBC Cancer Prevention Study Group. The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. The ATBC Cancer Prevention Study Group. *Ann Epidemiol* 1994;4:1–10. [PubMed: 8205268]
23. World Health Organization. International classification of diseases : ninth revision: basic tabulation list with alphabetical index. Geneva: 1978.
24. Percy, C.; Van Holten, V.; Muir, CS. International classification of diseases for oncology : ICD–O. 2. Geneva: World Health Organization; 1990.
25. Limburg P, Qiao Y, Mark S, et al. Helicobacter pylori seropositivity and subsite-specific gastric cancer risks in Linxian, China. *J Natl Cancer Inst* 2001;93:226–33. [PubMed: 11158192]
26. Kamangar F, Diaw L, Wei WQ, et al. Serum pepsinogens and risk of esophageal squamous dysplasia. *Int J Cancer* 2009;124:456–60. [PubMed: 18844222]
27. Romero-Gallo J, Perez-Perez GI, Novick RP, Kamath P, Norbu T, Blaser MJ. Responses of endoscopy patients in Ladakh, India, to Helicobacter pylori whole-cell and Cag A antigens. *Clin Diagn Lab Immunol* 2002;9:1313–7. [PubMed: 12414766]
28. Aiken, LS.; West, SG.; Reno, RR. Multiple regression: testing and interpreting interactions. Thousand Oaks ; London: SAGE; 1991.
29. Greenland S. Interactions in epidemiology: relevance, identification, and estimation. *Epidemiology* 2009;20:14–7. [PubMed: 19234397]
30. Samsonov VA, Makeeva RP, Sil'vestrov VS. Gastric mucosa in esophageal cancer. *Arkh Patol* 1979;41:37–43. [PubMed: 444086]
31. Rakic S, Dunjic MS, Pesko P, Milicevic M. Atrophic chronic gastritis in patients with epidermoid carcinoma of the esophagus. *J Clin Gastroenterol* 1993;17:84. [PubMed: 8409305]
32. Hsing AW, Hansson LE, McLaughlin JK, et al. Pernicious anemia and subsequent cancer. A population-based cohort study. *Cancer* 1993;71:745–50. [PubMed: 8431855]
33. Dawsey SM, Lewin KJ, Wang GQ, et al. Squamous esophageal histology and subsequent risk of squamous cell carcinoma of the esophagus. A prospective follow-up study from Linxian. *China Cancer* 1994;74:1686–92.
34. Wang GQ, Abnet CC, Shen Q, et al. Histological precursors of oesophageal squamous cell carcinoma: results from a 13 year prospective follow up study in a high risk population. *Gut* 2005;54:187–92. [PubMed: 15647178]
35. Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. *Endoscopy* 1969;3:87–97.
36. Plummer M, Buiatti E, Lopez G, et al. Histological diagnosis of precancerous lesions of the stomach: A reliability study. *Int J Epidemiol* 1997;26:716–20. [PubMed: 9279602]
37. Cassaro M, Di Mario F, Leandro G, Genta RM, Rugge M. The dark side of the gastric biopsy. *Hum Pathol* 1999;30:741–4. [PubMed: 10414491]
38. Guarner J, Herrera-Goepfert R, Mohar A, et al. Gastric atrophy and extent of intestinal metaplasia in a cohort of Helicobacter pylori-infected patients. *Hum Pathol* 2001;32:31–5. [PubMed: 11172292]
39. de Vries AC, Haringsma J, de Vries RA, et al. The use of clinical, histologic, and serologic parameters to predict the intragastric extent of intestinal metaplasia: a recommendation for routine practice. *Gastrointest Endosc* 2009;70:18–25. [PubMed: 19249770]

40. Ye W, Held M, Enroth H, Kraaz W, Engstrand L, Nyren O. Histology and culture results among subjects with antibodies to CagA but no evidence of *Helicobacter pylori* infection with IgG ELISA. *Scand J Gastroenterol* 2005;40:312–8. [PubMed: 15932172]
41. Iijima K, Koike T, Abe Y, et al. Gastric Hyposecretion in Esophageal Squamous-Cell Carcinomas. *Dig Dis Sci*. 2009
42. Yokoyama A, Yokoyama T, Omori T, et al. *Helicobacter pylori*, chronic atrophic gastritis, inactive aldehyde dehydrogenase-2, macrocytosis and multiple upper aerodigestive tract cancers and the risk for gastric cancer in alcoholic Japanese men. *J Gastroenterol Hepatol* 2007;22:210–7. [PubMed: 17295873]
43. Satoh K, Kimura K, Taniguchi Y, et al. Distribution of inflammation and atrophy in the stomach of *Helicobacter pylori*-positive and -negative patients with chronic gastritis. *Am J Gastroenterol* 1996;91:963–9. [PubMed: 8633589]
44. Bayerdorffer E, Lehn N, Hatz R, et al. Difference in expression of *Helicobacter pylori* gastritis in antrum and body. *Gastroenterology* 1992;102:1575–82. [PubMed: 1568567]
45. Rathinavelu S, Zavros Y, Merchant JL. *Acinetobacter lwoffii* infection and gastritis. *Microbes and Infection* 2003;5:651–7. [PubMed: 12787741]
46. Yeomans ND, Brimblecombe RW, Elder J, et al. Effects of acid suppression on microbial flora of upper gut. *Dig Dis Sci* 1995;40:81S–95S. [PubMed: 7859586]
47. Husebye E. The pathogenesis of gastrointestinal bacterial overgrowth. *Chemotherapy* 2005;51 (Suppl 1):1–22. [PubMed: 15855746]
48. Nehra D, Howell P, Williams CP, Pye JK, Beynon J. Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity. *Gut* 1999;44:598–602. [PubMed: 10205192]
49. Hashimoto N, Inayama M, Fujishima M, et al. Esophageal cancer after distal gastrectomy. *Dis Esophagus* 2006;19:346–9. [PubMed: 16984530]
50. Wu LH, Xu ZF, Zhao XW, Li JQ, Sun YC. Surgical Treatment and Prognosis of Esophageal Cancer After Distal Gastrectomy. *J Gastrointest Surg* 2010;14:32–7. [PubMed: 19756882]
51. Sears RJ, Champion GL, Richter JE. Characteristics of distal partial gastrectomy patients with esophageal symptoms of duodenogastric reflux. *Am J Gastroenterol* 1995;90:211–5. [PubMed: 7847287]
52. Miwa K, Sahara H, Segawa M, et al. Reflux of duodenal or gastro-duodenal contents induces esophageal carcinoma in rats. *Int J Cancer* 1996;67:269–74. [PubMed: 8760598]
53. Yamashita Y, Homma K, Kako N, et al. Effect of duodenal components of the refluxate on development of esophageal neoplasia in rats. *J Gastrointest Surg* 1998;2:350–5. [PubMed: 9841992]
54. Pera M, Trastek VF, Carpenter HA, et al. Influence of pancreatic and biliary reflux on the development of esophageal carcinoma. *Ann Thorac Surg* 1993;55:1386–92. discussion 92–3. [PubMed: 8512386]
55. Chen KH, Mukaisho K, Ling ZQ, Shimomura A, Sugihara H, Hattori T. Association between duodenal contents reflux and squamous cell carcinoma—establishment of an esophageal cancer cell line derived from the metastatic tumor in a rat reflux model. *Anticancer Res* 2007;27:175–81. [PubMed: 17352229]
56. Galli J, Cammarota G, Calò L, et al. The Role of Acid and Alkaline Reflux in Laryngeal Squamous Cell Carcinoma. *The Laryngoscope* 2002;112:1861–5. [PubMed: 12368631]
57. Cianci R, Galli J, Agostino S, et al. Gastric surgery as a long-term risk factor for malignant lesions of the larynx. *Arch Surg* 2003;138:751–4. discussion 5. [PubMed: 12860756]
58. Galli J, Calò L, Agostino S, et al. Bile reflux as possible risk factor in laryngopharyngeal inflammatory and neoplastic lesions. *Acta Otorhinolaryngol Ital* 2003;23:377–82. [PubMed: 15108488]
59. Cammarota G, Galli J, Cianci R, et al. Association of laryngeal cancer with previous gastric resection. *Ann Surg* 2004;240:817–24. [PubMed: 15492563]

Figure 1. The association between pepsinogen I and the risk of esophageal squamous cell carcinoma

Pepsinogen I (PGI) [μg/L] was plotted on a reverse linear scale and the odds of esophageal squamous cell carcinoma was plotted on a logarithmic scale. The vertical lines demarcate the 25th, 50th, and 75th percentiles of PGI in control subjects.

Figure 2. The association between pepsinogen II and the risk of esophageal squamous cell carcinoma

Pepsinogen II (PGII) [µg/L] was plotted on a linear scale and the odds of esophageal squamous cell carcinoma was plotted on a logarithmic scale. The vertical lines demarcate the 25th, 50th, and 75th percentiles of PGII in control subjects.

Figure 3. The association between pepsinogen I:II ratio and the risk of esophageal squamous cell carcinoma

The pepsinogen I:II ratio was plotted on a reverse linear scale and the odds of esophageal squamous cell carcinoma was plotted on a logarithmic scale. The vertical lines demarcate the 25th, 50th, and 75th percentiles of the PGI:PGII ratio in control subjects.

Table 1

Descriptive characteristics of controls and esophageal squamous cell carcinoma cases nested in the ATBC Study.

Variable	Controls	ESCC
Total, N	94	79
Mean age in years (s.d.)	58.1 (4.8)	57.7 (4.6)
Mean years of smoking (s.d.)	36.7 (8.5)	37.1 (8.2)
Mean cigarettes per day (s.d.)	20.1 (10.3)	21.3 (7.4)
Alcohol, grams of ethanol/day (s.d.)	16.6 (17.3)	30.4 (29.7)
Education -post-elementary school, N (%)	16 (17.0)	11 (13.9)
Body mass index (s.d.)	26.4 (3.9)	25.6 (4.0)
Fruit, grams/day (s.d.)	268.7 (247.5)	189.7 (182.4)
Vegetables, grams/day (s.d.)	319.6 (114.0)	278.0 (105.8)

Abbreviations: ESCC, esophageal squamous cell carcinoma; s.d., standard deviation.

Association of pre-diagnostic serum pepsinogens and *Helicobacter pylori* with subsequent esophageal squamous cell carcinoma in the ATBC Study.

Table 2

Analysis	ESCC									
	Minimally Adjusted					Fully Adjusted				
	Controls	Cases	OR	95%CI	P value	Controls	Cases	OR	95%CI	P value
Pepsinogen I										
PGI Continuous per unit decrease [#]	93	79	1.43	1.13 – 1.81	0.003	89	72	1.49	1.13 – 1.96	0.004
PGI >75th percentile (152)	23	9	Referent			21	8	Referent		
PGI ≤ 75th percentile (152)	70	70	2.52	1.08 – 5.87	0.033	68	64	3.37	1.19 – 9.54	0.022
PGI >50th percentile (106)	46	25	Referent			44	23	Referent		
PGI ≤ 50th percentile (106)	47	54	2.13	1.13 – 4.03	0.020	45	49	2.09	1.01 – 4.33	0.047
PGI >70	74	51	Referent			71	45	Referent		
PGI ≤ 70	19	28	2.22	1.10 – 4.48	0.025	18	27	2.37	1.07 – 5.23	0.033
PGI >50	81	56	Referent			78	50	Referent		
PGI ≤ 50	12	23	2.86	1.29 – 6.30	0.009	11	22	3.68	1.51 – 8.97	0.004
PGI >30	86	61	Referent			83	54	Referent		
PGI ≤ 30	7	18	3.63	1.42 – 9.29	0.007	6	18	5.12	1.79 – 14.67	0.002
PGI ≥ 151.85	23	9	Referent			21	8	Referent		
PGI ≥ 105.30 & <151.85	24	17	1.77	0.65 – 4.79	0.260	24	16	2.65	0.80 – 8.80	0.111
PGI ≥ 73.58 & <105.30	23	23	2.50	0.94 – 6.64	0.066	22	20	3.00	0.94 – 9.59	0.063
PGI <73.58	23	30	3.40	1.30 – 8.86	0.012	22	28	4.62	1.44 – 14.81	0.010
Pepsinogen II										
PGII Continuous per unit [#]	93	79	1.01	0.87 – 1.18	0.891	89	72	0.99	0.82 – 1.21	0.943
PGII >50th percentile (16.45)	47	35	Referent			45	30	Referent		
PGII ≤ 50th percentile (16.45)	46	44	1.27	0.69 – 2.36	0.440	44	42	1.58	0.79 – 3.18	0.197
PGII <10.57	23	12	Referent			21	11	Referent		
PGII ≥ 10.57 & <16.45	23	32	2.64	1.08 – 6.41	0.032	23	31	2.86	1.04 – 7.86	0.041
PGII ≥ 16.45 & <22.43	24	13	1.04	0.39 – 2.80	0.938	23	13	0.98	0.33 – 2.98	0.978
PGII ≥ 22.43	23	22	1.87	0.74 – 4.73	0.186	22	17	1.57	0.53 – 4.65	0.416
Pepsinogen I:II Ratio										
PGI:PGII Ratio Continuous per unit decrease [#]	93	79	1.52	1.23 – 1.87	<0.001	89	72	1.48	1.17 – 1.87	0.001

Analysis	ESCC									
	Minimally Adjusted					Fully Adjusted				
	Controls	Cases	OR	95%CI	P value	Controls	Cases	OR	95%CI	P value
PGR >75th percentile (8.85)	23	9		Referent		22	9		Referent	
PGR ≤ 75th percentile (8.85)	70	70	2.76	1.17 – 6.51	0.020	67	63	1.86	0.74 – 4.69	0.187
PGR >50th percentile (6.75)	46	24		Referent		44	23		Referent	
PGR ≤ 50th percentile (6.75)	47	55	2.28	1.21 – 4.29	0.011	45	49	1.89	0.94 – 3.80	0.073
PGE:PGII Ratio>5	68	40		Referent		65	38		Referent	
PGE:PGII Ratio ≤ 5	25	39	2.70	1.42 – 5.13	0.002	24	34	2.50	1.20 – 5.18	0.014
PGE:PGII Ratio>4	79	46		Referent		76	43		Referent	
PGE:PGII Ratio ≤ 4	14	33	4.11	1.98 – 8.54	<0.001	13	29	4.58	2.00 – 10.48	<0.001
PGE:PGII Ratio>3	82	56		Referent		79	49		Referent	
PGE:PGII Ratio ≤ 3	11	23	3.10	1.39 – 6.91	0.006	10	23	4.32	1.74 – 10.71	0.002
PGE:PGII Ratio>2	87	63		Referent		84	56		Referent	
PGE:PGII Ratio ≤ 2	6	16	3.62	1.34 – 9.81	0.011	5	16	5.16	1.70 – 15.66	0.004
PGE:PGII Ratio>3 or PGI>70	84	61		Referent		81	54		Referent	
PGE:PGII Ratio ≤ 3 & PGI ≤ 70	9	18	2.76	1.15 – 6.61	0.023	8	18	3.70	1.40 – 9.84	0.009
PGE:PGII Ratio>2 or PGI>30	88	63		Referent		85	56		Referent	
PGE:PGII Ratio ≤ 2 & PGI ≤ 30	5	16	4.40	1.53 – 12.70	0.006	4	16	6.28	1.90 – 20.77	0.003
PGE:PGII Ratio ≥ 8.85	23	9		Referent		22	9		Referent	
PGE:PGII Ratio ≥ 6.75 & <8.85	23	15	1.81	0.65 – 5.06	0.260	22	14	1.24	0.41 – 3.78	0.702
PGE:PGII Ratio ≥ 4.86 & <6.75	23	17	2.00	0.73 – 5.48	0.177	22	16	1.35	0.45 – 4.08	0.595
PGE:PGII Ratio<4.86	24	38	4.35	1.70 – 11.16	0.002	23	33	2.98	1.07 – 8.33	0.037
Pepsinogen I & II categorical										
High PGI (>106) and High PGII (>16.45)	32	19		Referent		30	17		Referent	
Low PGI (≤ 106) and High PGII (>16.45)	15	16	1.77	0.71 – 4.40	0.218	15	13	1.62	0.57 – 4.59	0.365
High PGI (>106) and Low PGII (≤ 16.45)	14	6	0.71	0.23 – 2.17	0.551	14	6	1.03	0.31 – 3.45	0.964
Low PGI (≤ 106) and Low PGII (≤ 16.45)	32	38	2.03	0.95 – 4.34	0.068	30	36	2.42	1.00 – 5.86	0.051
Helicobacter pylori										
negative	20	14		Referent		19	14		Referent	
positive	71	64	1.34	0.62 – 2.89	0.462	68	57	0.94	0.40 – 2.24	0.892
negative	20	14		Referent		19	14		Referent	

Analysis	ESCC									
	Minimally Adjusted					Fully Adjusted				
	Controls	Cases	OR	95%CI	P value	Controls	Cases	OR	95%CI	P value
whole cell positive & cagA negative	29	29	1.50	0.63 – 3.57	0.362	27	25	0.89	0.33 – 2.40	0.816
cagA positive	42	35	1.23	0.54 – 2.80	0.622	41	32	0.98	0.39 – 2.44	0.959

Odds ratios and 95% confidence intervals in the minimally adjusted models were estimated using unconditional logistic regression models with adjustment for the matching variables of age at randomization and date of blood draw. The fully adjusted models also included the covariates years of smoking, cigarettes per day, alcohol, education (dichotomous), body mass index, fruit intake, and vegetable intake. Unless otherwise specified, these exposures were modeled as continuous variables.

Each continuous unit was equal to half the distance between the 25th and 75th percentile values in the control subjects which translated to units of 38.99 µg/L for PGI, 5.93 µg/L for PGI, and 2.00 for the PGI:PGII ratio. All PGI and PGII units are in µg/L.

Table 3

Studies which have formally tested the relationship between gastric atrophy, severity of gastric atrophy and ESCC.

First Author	Year of Publication	Population	Study Design	Controls/ Cohort (n)	Cases (n)	Ascertainment of Gastric Atrophy	Effect of Gastric Atrophy on ESCC risk	Risk Estimates	Ascertainment of Atrophic Severity	Effect of Increasing Gastric Atrophy Severity on ESCC risk	Risk Estimates
Ye, W	2004	Sweden	Case-Control	499	85	PGI	↑	PGI <28 µg/L vs PGI 28–158 µg/L; OR=4.3, 95%CI:1.9–9.6	-	-	-
Iijima, K	2007	Japanese	Case-Control	73	73	PGI /Histology (1 biopsy)	↑ /↑	PGI <25 µg/L vs PGI ≥ 25 µg/L; OR=8.2 (95%CI:2.2–30.1). Histologic Atrophy: OR=4.2 (95%CI:1.5–11.7).	PGI * /Histology (1 biopsy; GA /IM)	null /↑	PGI quartiles *: OR _{Q1} =referent; OR _{Q2} =0.5 (95%CI:0.1–2.0); OR _{Q3} =0.7 (95%CI:0.2–2.8); OR _{Q4} =7.6 (95%CI:1.6–35.7). Gastric Atrophy: OR=4.2 (1.5–11.7). Intestinal Metaplasia: OR=10.7 (95%CI:2.3–50.4).
de Vries, AC	2009	The Netherlands	Cohort	97,728	126	Histology (variable biopsy number)	↑	Histologic Atrophy: OR=2.2 (95%CI:1.8– 2.6)	Histology (variable biopsy number; GA /IM /DYS)	null	Gastric Atrophy: OR=2.3 (95%CI:1.6–3.3). Intestinal Metaplasia: OR=2.1 (95%CI:1.7–2.6). Dysplasia: OR=2.3 (95%CI:1.4–4.0).
Ren, JS	2009	China	Case-Cohort	1,050	300	PGI:PGII	↑	PGI:PGII ≤ 4 vs PGI:PGII >4:OR=1.6 (95%CI:1.0–2.0).	PGI:PGII	null	PGI:PGII ≤ 3 vs PGI:PGII >3: OR=1.1 (95%CI: 0.6–2.0). PGI:PGII ≤4 vs PGI:PGII >4: OR=1.6 (95%CI: 1.0–2.0). PGI:PGII ≤5 vs PGI:PGII >5: OR=1.4 (95%CI: 1.0–2.0). PGI:PGII ≤6 vs PGI:PGII >6: OR=1.1 (95%CI: 0.8–1.5).
Yokoyama, A	2009	Japan	Case-Control	99	180	PGI:PGII	↑	PGI <30 µg/L & PGI:PGII <2 vs PGI ≥ 30 µg/L or PGI:PGII ≥ 2: OR=3.2** (95%CI:1.6–6.4)	PGI:PGII	↑	PGI <70 µg/L & PGI:PGII <3 vs PGI ≥ 70 µg/L or PGI:PGII ≥ 3:OR=1.5** (95%CI:0.9–2.6). PGI <30 µg/L & PGI:PGII <2 vs PGI ≥ 30 µg/L or PGI:PGII ≥ 2: OR=3.2** (95%CI:1.6–6.4).
Akiyama, T	2009	Japan	Case-Control	253	253	-	-	-	Endoscopic extent of GA	↑	GA Open-type 2 or 3 vs all other GA types or no GA: OR=1.6 (95%CI:1.0–2.4)
Cook, MB	2010	Finland	Nested Case- Control	93	79	PGI:PGII	↑	See Table 2 herein	PGI:PGII	↑	See Table 2 and Figures herein

* Personal Communication: Dr. K. Iijima. Tohoku University Graduate School of Medicine, Japan, December 2009.

** Crude odds ratios were estimated by the current authors from data presented in Yokoyama et al. 2009, Table 1. Abbreviations: ESCC, esophageal squamous cell carcinoma; OR, odds ratio; 95%CI, 95% confidence interval; PG, pepsinogen; GA, gastric atrophy; IM, intestinal metaplasia; DYS, dysplasia.